Home
  1. Cornerstone publishes in Infection Control & Hospital Epidemiology. “Lack of Increased Colonization with Vancomycin-Resistant Enterococci during Preferential Use of Vancomycin for Treatment during an Outbreak of Healthcare-Associated Clostridium difficile Infection”

  2. Cornerstone publishes in BMC Musculoskeletal Disease. “Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study.”

  3. Cornerstone Research Group would like to welcome Nicole Ferko as a senior, full-time member of our rapidly growing team. Nicole brings with her over 6 years of consulting experience in health economics, with a focus on the management of global modeling and reimbursement activities, as well as communication of research through abstracts, presentations and peer-reviewed publications. She is a graduate of the Biology and Pharmacology Co-op Program at McMaster University, where she also earned a M.Sc. in Health Research Methodology.

  4. Cornerstone Research Group is pleased to welcome Stephen Brown to our growing team. Stephen received both his Ph.D. and M.Sc. from McMaster University, and has over 10 years of academic research experience. He recently left his role as a postdoctoral fellow and brings with him expertise in the areas of neuroscience, electrophysiology, cardiovascular disease, cancer, and molecular biology and is eager to apply these skills in his new role at CRG.

  5. Cornerstone Research Group would like to welcome Sabina Vohra-Miller to our growing team. Sabina recently graduated with a Masters in Pharmaceutical Sciences from the University of Toronto. With a strong background in clinical pharmacology and biomedical toxicology, Sabina brings with her comprehensive experience in conducting research and managing clinical trials and is eager to employ these skills to her new position at CRG.

  6. Challenges in Assessing Cost-effectiveness of Therapies for End-stage Renal Disease Patients Receiving Dialysis: A Case Study of Sevelamer for the Treatment of Hyperphosphatemia. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, Atlanta, Georgia, May 2010.

  7. Impact of Sevelamer on Hospitalization and In-center Dialysis Utilization: A Modeled Study Based on DCOR Presented at the National Kidney Foundation (NKF) 2010 Spring Clinical Meetings, Orlando, Florida, April 2010.

  8. Challenges in Assessing Cost-Effectiveness of Therapies for Dialysis Patients: A Case Study of Sevelamer for the Treatment of Hyperphosphatemia. Presented at the Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium, Halifax, Nova Scotia, April 2010.

  9. Cost-Effectiveness Analysis of Sevelamer for the Treatment of Hyperphosphatemia in Older Canadian Patients with End-Stage Renal Disease. Presented at the Canadian Association for Population Therapeutics (CAPT) Annual Conference, Toronto, Ontario, March 2010.

  10. It is with great pride that we announce Cornerstone’s 5 year anniversary. Since 2005, Cornerstone has grown not only in size from 2 to 12 people but in scope to reflect the evolving marketplace. Building upon a well-established core strength in health economic research, Cornerstone has expanded its service offerings to include medical writing and health economic marketing. We would like to thank our clients for supporting Cornerstone in its continued growth as a leader in health economic research and communications.

  11. Hutchison CA, Airia P, Cockwell P, Grima DT. Free Light Chain Removal by High Cut-Off Hemodialysis is Associated with High Rates of Renal Recovery in Patients with Renal Failure Secondary to Multiple Myeloma. Presented at the American Society of Nephrology, Renal Week, October 2009.

  12. A UK Cost-effectiveness Analysis of Sevelamer as a First-line Treatment for Hyperphosphatemia in Patients with End-stage Renal Disease, presented at the American Society for Nephrology 42nd Annual Meeting & Scientific Exposition, San Diego, California, October 27-November 1, 2009.


  13. Three posters were recently presented at ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009. One of these posters was awarded a finalist ribbon.

    • Cost Effectiveness Analysis of Bortezomib in Previously Untreated Multiple Myeloma Patients in Canada, presented at ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009.

    • US and Canadian Cost-effectiveness Analyses of US Oncology Trial 9735 Provide Additional Rationale for the Use of Taxanes in the Adjuvant Treatment of Operable Breast Cancer, presented at ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009.

    • Cost-effectiveness Analysis of Enoxaparin (Lovenox?) for Extended Prophylaxis of Venous Thromboembolism After Elective Total Hip Replacement Surgery, presented at ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009.


  14. We’re growing again! Cornerstone Research Group welcomes another member to its talented team.
    Cornerstone Research Group would like to welcome Michael Duong to our growing team. Michael has recently obtained his Ph.D. in Medical Sciences from McMaster University where he also graduated with a B.Sc. from the Biology and Pharmacology Co-op program. With his research experience in both academia and industry, Michael brings with him an expertise in neuroscience, pharmacology and molecular sciences, and is excited to translate these skills to his new opportunity at CRG.

  15. Long-Term Survival Benefits of Docetaxel plus Cyclophosphamide Compared to Doxorubicin plus Cyclophosphamide in the Adjuvant Treatment of Operable Breast Cancer: A US Cost-Effectiveness Analysis of US Oncology Trial 9735, presented at the ASCO ’09 Annual Meeting, Orlando, Florida, USA, May 29-June 2, 2009.

  16. Docetaxel Plus Cyclophosphamide is Cost-effective Versus Doxorubicin Plus Cyclophosphamide in the Adjuvant Treatment of Operable Breast Cancer: A US Economic Analysis of US Oncology Adjuvant Trial 9735, presented at ISPOR 14th Annual Meeting. Orlando, Florida, USA, May 16-20, 2009.

  17. Lower Hip Fracture Rates in the First Year of Therapy Translate into Favorable Cost-Effectiveness for Risedronate vs. Generic Alendronate Among High Risk Patients, presented at ISPOR 14th Annual Meeting. Orlando, Florida, USA, May 16-20, 2009.

  18. Cornerstone is pleased to welcome Parisa Airia to our team. Parisa is a PhD candidate in Epidemiology at the University of Toronto, having previously completed an MSc in Community Health Sciences from University of Manitoba and an MD from Tehran University. She brings an expertise in data analysis highlighted by her previous graduate work in the areas of disease risk factors, prevention, and treatment at universities of Tehran, Manitoba, and Toronto as well as cancer care centers in Manitoba and Ontario.

  19. We have moved to accommodate continued growth. Our new address is: Suite 204, 3228 South Service Road, Burlington, Ontario, L7N 3H8.

  20. Docetaxel Plus Cyclophosphamide is Cost-effective Compared to Doxorubicin Plus Cyclophosphamide, Based on an Economic Analysis of US Oncology Trial 9735: Additional Rationale to Avoid Anthracyclines in the Adjuvant Treatment of Operable Breast Cancer?, presented at the 31st San Antonio Breast Cancer Symposium (SABCS). San Antonio, Texas, USA, December 10-14, 2008.

  21. Docetaxel Plus Cyclophosphamide is Cost-effective Versus Doxorubicin Plus Cyclophosphamide in the Adjuvant Treatment of Operable Breast Cancer: A Canadian Economic Analysis of US Oncology Adjuvant Trial 9735, presented at 5th Canadian Therapeutics Congress. Quebec City, July 27-August 1, 2008.

  22. Increased Adverse Events and Treatment Discontinuation in Patients Switched from Branded Alendronate to Generic Alendronate, presented at 5th Canadian Therapeutics Congress. Quebec City, July 27-August 1, 2008.

  23. How many cardiovascular events can be prevented with optimal management of high-risk Canadians?,
    published in Can J Cardiol. 2008;24(5):363-8.

  24. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis, published in Osteoporos Int. 2008;19(5):687-97.

  25. Pharmacoeconomic Modeling - Application to Price Setting and Clinical Trial Development, presented at the CBI Effective Product Pricing and Modeling Strategies conference, Philadelphia, April 10-11, 2008.

  26. Pricing Considerations in Early Product Development: The Advent of Value-Based Pricing, presented at the CBI Early Stage Commercialization conference, Philadelphia, Feb 25-26, 2008.